A clinical study has reported that a combination therapy of osimertinib and cetuximab for a patient with an EGFR exon 20 mutation demonstrated efficient anti-tumor efficacy and that this promising result highlights the potential of this combination therapy [15]. Here, EGFR is linked to neoplasm.